Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-Avibactam in Febrile Neutropenic Adults With Cancer
NCT02732327Phase 2Terminated
- Sponsor
- Forest Laboratories
- Start
- May 2016
- Primary completion
- Jun 2016
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ceftazidime + avibactam in febrile neutropenia (FN) (2 arms), sponsored by Forest Laboratories. Primary endpoint: Percentage of Patients With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV) at Day 14. Started May 2016; status: terminated.
02
Drugs
ceftazidime + avibactam
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT02732327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02732327.